ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Disease May 8, 2019
ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 16, 2019
ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal April 8, 2019
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 4, 2019
ContraFect Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update March 14, 2019
ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens March 4, 2019
